个人简述:

刘丹，女，博士，副教授。2000年毕业于沈阳药科大学，获化学制药学士学位，2000年考入沈阳药科大学药物化学专业硕士研究生，2002年直接攻读博士学位，2008年获沈阳药科大学药物化学博士学位，2009年进入天津天士力集团有限公司进行博士后研究。2005年留校任教，2011年晋升副教授，硕士研究生导师，2012年赴美国北卡罗来纳大学教堂山分校交流访问，现为制药工程学院药物化学教研室主任。作为课题负责人主持了国家自然科学基金项目2项，辽宁省科技厅项目2项，沈阳市科技厅项目1项，沈阳药科大学科研专项基金2项，另外，作为项目骨干成员参加国家科技部重大新药创制项目5项，科技部国际合作项目1项，国家自然科学基金面上项目5项。目前已在Nano Letters、ACS Applied Materials & Interfaces、European Journal of Medicinal Chemistry、Bioorganic & Medicinal Chemistry、Scientific Reports等期刊发表学术论文30余篇。

科研工作:

近年来发表代表性论文
1.Yang Jinyu, Cheng Gaoliang,Xu Qihao, Luan Shenglin, Wang Shuxiang, LiuDan*, Zhao Linxiang*. Design, synthesis and biological evaluation of novelhydroxamic acid based histone deacetylase 6 selective inhibitors bearingphenylpyrazol scaffold as surface recognition motif. Bioorganic & MedicinalChemistry, 2018, 26(8):1418-1425. (IF=2.486)2.Shenglin Luan, Hang Zhong,Xuan Zhao, Jinyu Yang, Yongkui Jing, DanLiu*, Linxiang Zhao*. Synthesis, anticancer evaluation and pharmacokineticstudy of novel 10-O-phenyl ethers of dihydroartemisinin. European Journal ofMedicinal Chemistry. 2017, 141: 584-595. (IF=4.519)3.XiangfeiHan, Jinling Chen, Mengjuan Jiang, Na Zhang, Kexin Na, Cong Luo, Ruoshi Zhang,Mengchi Sun, Guimei Lin, Rong Zhang, Yan Ma, Dan Liu*, and Yongjun Wang*, Paclitaxel−paclitaxel prodrug nanoassembly as a versatilenanoplatform for combinational cancer therapy. ACS Applied Materials &Interfaces. 2016, 8: 33506−33513. (IF=7.504)4.Kun Li, Lei Li,Shuxiang Wang, Xiaojing Li, Tianyi Ma, DanLiu*, Yongkui Jing*, Linxiang Zhao*, Design and synthesis of novel 2-substituted11-keto-boswellic acid heterocyclic derivatives as anti-prostate cancer agentswith Pin1 inhibition ability. European Journal of Medicinal Chemistry. 2016,126: 910-919. (IF=4.519)5.Yin-bo Fan, MinHuang, Yu Cao, Ping Gong, Wen-bing Liu, Shu-yu Jin, Jia-chen Wen, Yong-kuiJing, Dan Liu*, Lin-xiang Zhao*.Usnic acid is a novel Pim-1 inhibitor with the abilities of inhibiting growthand inducing apoptosis in human myeloid leukemia cells. RSC Advances,2016,6,24091-24096. (IF= 3.108)6.Jiachen Wen, Yu Bao, Qun Niu, Jinyu Yang, Yinbo Fan, Jinhua Li, YongkuiJing*, Linxiang Zhao*, Dan Liu*. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potenthistone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.European Journal of Medicinal Chemistry, 2016, 109: 350-359. (IF=4.519)7.Hang Zhong, Xuan Zhao, Zhizhong Zuo, Jingwei Sun, Yao Yao, Tao Wang, Dan Liu*, Linxiang Zhao*. Combating P-glycoprotein-mediated multidrug resistancewith 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells. European Journal ofMedicinal Chemistry. 2016, 108:720-729. (IF=4.519)8.Qiang Fu, YongjunWang*, Yan Ma, D. Zhang, J. K. Fallon, Xinggang Yang, Dan Liu*, Zhonggui He & Feng Liu. Programmed hydrolysis indesigning paclitaxel prodrug for nanocarrier assembly. Scientific Reports,2015, DOI: 10.1038/srep12023. (IF 5.228)9.Yongjun Wang*†, Dan Liu†, QingchuanZheng, Qiang Zhao, Hongjuan Zhang, Yan Ma, John K. Fallon, Qiang Fu, Matthew T.Haynes, Guimei Lin, Rong Zhang, Dun Wang, Xinggang Yang, Linxiang Zhao,Zhonggui He,* and Feng Liu, Disulfide bond bridge insertion turns hydrophobicanticancer prodrugs into self-assembled nanomedicines. Nano Letters, 2014, 14:5577-5583. (IF=13.592)（Author Contributions：∥Y.W. and D.L.contributed equally to this work）10.Ma, Yan† Liu, Dan† Wang, Dun Wang, YongjunFu, Qiang Fallon, John Yang, Xingang He, Zhonggui Liu, Feng*. Combinational delivery of Hydrophobic and HydrophilicAnticancer Drugs in Single Nanoemulsions to Treat MDR in Cancer. MolecularPharmaceutics, 2014, 11, 2623-2630.(IF=4.44)（Author Contributions：∥Y.M. and D.L. contributedequally to this work）